- Home
- WKEY vs BIAF Comparison
WKEY vs BIAF Comparison
Compare WKEY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WKEY | BIAF |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.4M | 6.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | WKEY | BIAF |
|---|---|---|
| Price | $7.83 | $1.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 360.0K | 87.9K |
| Earning Date | 09-23-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,994,000.00 | $6,776,739.00 |
| Revenue This Year | $32.29 | N/A |
| Revenue Next Year | $89.83 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $1.25 |
| 52 Week High | $19.80 | $46.53 |
Technical Indicators
Market Signals| Indicator | WKEY | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 40.46 |
| Support Level | $8.25 | $1.60 |
| Resistance Level | $10.05 | $1.74 |
| Average True Range (ATR) | 0.83 | 0.12 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 1.33 | 37.79 |
Price Performance
Historical ComparisonAbout WKEY WISeKey International Holding Ltd
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.